These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6949614)

  • 41. Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo.
    Wang YF; Curtis JE; Lipton J; Minkin S; McCulloch EA
    Leukemia; 1991 Jun; 5(6):522-7. PubMed ID: 1711641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Letter: High remission rate in acute myeloid leukemia (AML) by adriamycin, vincristine and cytosine arabinoside combination. Importance of intensive hematological care].
    Mathé G; Pouillart P; De Vassal F; Delgado M; Schwarzenberg L; Misset JL; Hayat M
    Nouv Presse Med; 1976 Aug 28-Sep 4; 5(28):1758. PubMed ID: 1066659
    [No Abstract]   [Full Text] [Related]  

  • 43. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Cahn JY; Labopin M; Sierra J; Blaise D; Reiffers J; Ferrant A; Bergmann L; Visani G; Cornelissen J; De Witte T; Bosi A; Frassoni F; Gorin NC
    Br J Haematol; 2000 Aug; 110(2):308-14. PubMed ID: 10971386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of stem cell factor on leukemic progenitor cell growth and sensitivity to cytosine-arabinoside.
    Viallard JF; Grosset C; Lacombe F; David S; Mahon FX; Barbot C; Vianes I; Dupouy M; Reiffers J
    Leuk Res; 1996; 20(11-12):915-23. PubMed ID: 9009249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Review of clinical and haematological response to low-dose cytosine arabinoside in acute myeloid leukaemia.
    Shtalrid M; Lotem J; Sachs L; Berrebi A
    Eur J Haematol; 1987 Jan; 38(1):3-11. PubMed ID: 3472902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of recombinant human tumor necrosis factor on the self-renewal capacity of leukemia blast progenitors in acute myeloblastic leukemia.
    Nagata K; Tohda S; Suzuki T; Nara N
    Leukemia; 1989 Sep; 3(9):626-30. PubMed ID: 2761317
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of interferon on colony formation in culture by blast cell progenitors in acute myeloblastic leukemia.
    Taetle R; Buick RN; McCulloch EA
    Blood; 1980 Sep; 56(3):549-52. PubMed ID: 6157445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro culture of clonogenic leukaemic cells in acute myeloid leukaemia: growth pattern and drug sensitivity.
    Marie JP; Zittoun R; Thevenin D; Mathieu M; Viguie F
    Br J Haematol; 1983 Nov; 55(3):427-37. PubMed ID: 6580036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intracellular cytarabine triphosphate in circulating blasts post-treatment predicts remission status in patients with acute myeloid leukemia.
    Anderson E; Rees B; Hull J; Heywood J; Preston A; Protheroe R; Foulstone E; Greenwood R; Salisbury V; Mehta P
    Exp Hematol; 2019 Jun; 74():13-18.e3. PubMed ID: 31054867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.
    Karp JE; Donehower RC; Dole GB; Burke PJ
    Blood; 1987 Apr; 69(4):1134-40. PubMed ID: 3470054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High dose cytosine arabinoside in the management of refractory acute leukaemia.
    Willemze R; Zwaan FE; Colpin G; Keuning JJ
    Scand J Haematol; 1982 Aug; 29(2):141-6. PubMed ID: 6958004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contributions of host- and disease-related attributes to the outcome of patients with acute myelogenous leukemia.
    Curtis JE; Messner HA; Hasselback R; Elhakim TM; McCulloch EA
    J Clin Oncol; 1984 Apr; 2(4):253-9. PubMed ID: 6368758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
    te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
    Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
    Yang GS; Minden MD; McCulloch EA
    Leukemia; 1994 Dec; 8(12):2065-75. PubMed ID: 7807996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia.
    Inatomi Y; Toyama K; Clark SC; Shimizu K; Miyauchi J
    Cancer Res; 1994 Jan; 54(2):455-62. PubMed ID: 7506123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autocrine growth mechanisms of the progenitors of blast cells in acute myeloblastic leukemia.
    Murohashi I; Tohda S; Suzuki T; Nagata K; Yamashita Y; Nara N
    Blood; 1989 Jul; 74(1):35-41. PubMed ID: 2473799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside.
    Andreeff M; Tafuri A; Hegewisch-Becker S
    Haematol Blood Transfus; 1990; 33():747-62. PubMed ID: 2323674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant human granulocyte colony-stimulating factor in combination with continuous infusion of cytosine arabinoside for the treatment of refractory acute myelogenous leukemia.
    Goto H; Shimazaki C; Hirata T; Ashihara E; Ohkawa K; Oku N; Inaba T; Fujita N; Nakagawa M
    Acta Haematol; 1993; 89(3):144-8. PubMed ID: 7689779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.